Literature DB >> 18468627

Effects of amrinone in an experimental model of hepatic ischemia-reperfusion injury.

Can Kucuk1, Alper Akcan, Hizi Akyýldýz, Hulya Akgun, Sebahattin Muhtaroglu, Erdogan Sozuer.   

Abstract

BACKGROUND: During some surgical interventions, temporary occlusion of the hepatic blood supply may cause ischemia-reperfusion (IR) injury. Recent studies suggest that type 3 phosphodiesterase inhibitors may have a beneficial effect on liver IR injury. The aim of this study was to investigate whether amrinone, a type 3 phosphodiesterase inhibitor, could have a protective effect on liver having experimental liver IR injury.
MATERIALS AND METHODS: Sixty Wistar albino rats were randomly divided into three groups. The IR and amrinone groups were subjected to 1 h total hepatic ischemia, followed by 2 h of reperfusion. The sham group underwent midline laparotomy only. Amrinone 10 microg/kg/min was infused to the amrinone group during the 3 h of the IR period. Histopathological examination, biochemical liver function, and liver adenosine triphosphate concentration after reperfusion and survival rate on the seventh day after the IR insult were recorded.
RESULTS: Serum aspartate aminotransferase, alanine aminotransferase, lactic dehydrogenase levels, and histological damage scores in the amrinone and IR groups were significantly higher compared with the sham group (P < 0.01). However, all of these values were significantly lower in the amrinone group than in the IR group (P < 0.05). Liver adenosine triphosphate levels and the rat survival rate in the amrinone and IR groups were significantly lower than those in the sham group (P < 0.01). However, these values were significantly higher in the amrinone group compared to those in the IR group (P < 0.01).
CONCLUSIONS: These results suggest that amrinone plays a significant role in the protection of liver against IR injury and that this treatment may be a novel pharmacological agent for safe and efficient liver surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468627     DOI: 10.1016/j.jss.2008.02.008

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  The hepatoprotective effects of Hypericum perforatum L. on hepatic ischemia/reperfusion injury in rats.

Authors:  Gokhan Bayramoglu; Aysegul Bayramoglu; Selin Engur; Hakan Senturk; Nilgun Ozturk; Suat Colak
Journal:  Cytotechnology       Date:  2013-06-23       Impact factor: 2.058

2.  Protective and therapeutic effects of milrinone on acoustic trauma in rat cochlea.

Authors:  Seyit Mehmet Ceylan; Erdal Uysal; Serdar Altinay; Efe Sezgin; Nagihan Bilal; Emine Petekkaya; Mehmet Dokur; Mahmut Alper Kanmaz; Mustafa Emre Gulbagci
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-06       Impact factor: 2.503

3.  Preventive role of gallic acid on hepatic ischemia and reperfusion injury in rats.

Authors:  Gokhan Bayramoglu; Hulyam Kurt; Aysegul Bayramoglu; Hasan Veysi Gunes; İrfan Degirmenci; Suat Colak
Journal:  Cytotechnology       Date:  2014-05-09       Impact factor: 2.058

4.  Pretreatment with a Phosphodiesterase-3 Inhibitor, Milrinone, Reduces Hepatic Ischemia-Reperfusion Injury, Minimizing Pericentral Zone-Based Liver and Small Intestinal Injury in Rats.

Authors:  Shinichi Nakanuma; Hidehiro Tajima; Hiroyuki Takamura; Seisho Sakai; Ryosuke Gabata; Mitsuyoshi Okazaki; Hiroyuki Shinbashi; Yoshinao Ohbatake; Isamu Makino; Hironori Hayashi; Tomoharu Miyashita; Sachio Fushida; Tetsuo Ohta
Journal:  Ann Transplant       Date:  2020-07-14       Impact factor: 1.530

5.  A Comparison of Network-Based Methods for Drug Repurposing along with an Application to Human Complex Diseases.

Authors:  Giulia Fiscon; Federica Conte; Lorenzo Farina; Paola Paci
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

6.  The effects of lycopene on hepatic ischemia/reperfusion injury in rats.

Authors:  Gokhan Bayramoglu; Aysegul Bayramoglu; Yılmaz Altuner; Mustafa Uyanoglu; Suat Colak
Journal:  Cytotechnology       Date:  2014-03-04       Impact factor: 2.058

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.